mevastatin has been researched along with Osteogenic Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, W; He, M; Jiang, X; Li, B; Liao, S; Lin, C; Liu, Y; Miao, J; Mo, Z; Qin, Z; Tang, H; Wei, Q; Xie, T; Xu, J | 1 |
| Abe, K; Asami, S; Kodama, T; Konishi, K; Oikawa, S; Sugiyama, M | 1 |
2 other study(ies) available for mevastatin and Osteogenic Sarcoma
| Article | Year |
|---|---|
A new insight of immunosuppressive microenvironment in osteosarcoma lung metastasis.
Topics: Bone Neoplasms; CD8-Positive T-Lymphocytes; Endothelial Cells; Humans; Immunosuppressive Agents; Lung Neoplasms; Osteosarcoma; Tumor Microenvironment | 2023 |
Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells.
Topics: Anti-Bacterial Agents; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Bone Neoplasms; Cloning, Molecular; Disulfides; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Indole Alkaloids; Lovastatin; Mevalonic Acid; Osteoporosis; Osteosarcoma; Pravastatin; Promoter Regions, Genetic; RNA, Messenger; Simvastatin; Transfection; Transforming Growth Factor beta; Tumor Cells, Cultured | 2000 |